1010 related articles for article (PubMed ID: 11729387)
21. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
22. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes.
Yeo JS; Chung JK; So Y; Kim S; Lee E; Lee DS; Youn YK; Hong SJ; Ahn IM; Lee MC; Cho BY
Head Neck; 2001 Feb; 23(2):94-103. PubMed ID: 11303639
[TBL] [Abstract][Full Text] [Related]
23. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
24. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
25. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
28. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
Hung MC; Wu HS; Kao CH; Chen WK; Changlai SP
Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
[TBL] [Abstract][Full Text] [Related]
30. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
31. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
Iwano S; Kato K; Ito S; Tsuchiya K; Naganawa S
Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
[TBL] [Abstract][Full Text] [Related]
33. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
Ong SC; Ng DC; Sundram FX
Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
[TBL] [Abstract][Full Text] [Related]
34. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
[TBL] [Abstract][Full Text] [Related]
35. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
36. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
Cabrera Martín MN; Pasamontes Pingarrón JA; Carreras Delgado JL; Lapeña Gutiérrez L; Delgado Bolton RC; Bittini Copano A; Pérez Castejón MJ; Fernández Pérez C
Rev Esp Med Nucl; 2007; 26(5):263-9. PubMed ID: 17910834
[TBL] [Abstract][Full Text] [Related]
38. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
[TBL] [Abstract][Full Text] [Related]
39. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
40. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]